Newly Diagnosed GBM Safety
In newly diagnosed GBM,
Optune Gio + TMZ was well-tolerated1,2
No significant increase in serious AEs compared with TMZ alone1,2
Optune Gio did not add systemic toxicity
- The most common device-related side effect with Optune Gio was mild-to-moderate skin irritation, which was typically manageable, reversible, and did not result in treatment discontinuation3
- The rate of grade 1/2 medical device site reaction was 52% for Optune Gio + TMZ compared with 0% for TMZ alone, and severe (grade 3) skin involvement occurred in 2% of patients treated with Optune Gio + TMZ2
- The overall most common (≥10%) AEs in the Optune Gio + TMZ arm were thrombocytopenia, nausea, constipation, vomiting, fatigue, asthenia, medical device site reaction, headache, convulsion, hemiparesis, and depression1,3
- A slightly higher incidence of grade 1 to 2 AEs was seen in some of the systems in the Optune Gio + TMZ arm of the study, but this is most likely a reflection of the longer duration of TMZ treatment due to the increase in PFS seen in the treatment group1
- Grade 3 to 4 AEs were well balanced between arms. None of the systemic grade 3 to 4 AEs were considered related to Optune Gio by any of the investigators1
Gill is an Optune Gio user and Patient Ambassador. Patient images reflect the health status of the patient at the time each photo was taken.
AEs, adverse events; dAEs, dermatologic adverse events; GBM, glioblastoma; TMZ, temozolomide.
References: 1. Optune Gio. Instructions For Use. Novocure; 2023. 2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306-2316. 3. Novocure Data on File OPT-103.